COPD - CCE - Certified Chronic Obstructive Pulmonary Disease Educator Pharmacological Management Questions and Answers — Questions and Answers
Question 1: A 68-year-old male with a significant smoking history is newly diagnosed with COPD. He reports getting short of breath when walking up a single flight of stairs (mMRC Grade 2) but has had no exacerbations in the past year. According to the 2023 GOLD guidelines, what is the most appropriate initial pharmacological treatment for this patient?
- A short-acting beta-agonist (SABA) as needed.
- A combination of a long-acting beta-agonist and a long-acting muscarinic antagonist (LABA/LAMA). (Correct answer)
- A combination of a long-acting beta-agonist and an inhaled corticosteroid (LABA/ICS).
- A long-acting muscarinic antagonist (LAMA) monotherapy.
Correct answer: A combination of a long-acting beta-agonist and a long-acting muscarinic antagonist (LABA/LAMA).
According to the 2023 GOLD Report, this patient falls into Group B, characterized by significant symptoms (mMRC ≥2) but low risk of exacerbation (0-1 moderate exacerbations not leading to hospitalization). The recommended initial therapy for Group B is a dual long-acting bronchodilator combination (LABA/LAMA), as this approach is more effective at improving symptoms than monotherapy.
Question 2: A patient with severe COPD and a history of frequent exacerbations (≥2 in the last year) is currently treated with a LABA/LAMA combination. Despite this treatment, they continue to experience exacerbations. Their blood eosinophil count is 150 cells/µL. Which of the following is the most appropriate next step in their pharmacological management?
- Add an inhaled corticosteroid (ICS) to the current regimen.
- Add a phosphodiesterase-4 (PDE4) inhibitor, such as roflumilast. (Correct answer)
- Switch from the LABA/LAMA to a LABA/ICS combination.
- Increase the dosage frequency of the current LABA/LAMA inhaler.
Correct answer: Add a phosphodiesterase-4 (PDE4) inhibitor, such as roflumilast.
For patients with persistent exacerbations on LABA/LAMA therapy, the next step depends on the blood eosinophil count. If the count is ≥100 cells/µL, adding an ICS is an option. However, for patients who continue to have exacerbations despite triple therapy or for those who are not candidates for ICS, adding a PDE4 inhibitor like roflumilast is recommended, particularly if they have chronic bronchitis.
Question 3: Which of the following medication classes is considered the cornerstone of pharmacological management for symptomatic COPD patients?
- Inhaled corticosteroids
- Oral corticosteroids
- Bronchodilators (Correct answer)
- Antibiotics
Correct answer: Bronchodilators
Bronchodilators are the central and foundational treatment for managing COPD symptoms. They work by relaxing the muscles around the airways, which helps to open them up and make breathing easier. This class includes both short-acting and long-acting beta-agonists and anticholinergics.
Question 4: A Certified COPD Educator is teaching a patient about potential side effects of their new tiotropium (a LAMA) inhaler. Which of the following side effects should the educator be sure to mention?
- Tachycardia and tremors
- Oral candidiasis (thrush)
- Weight gain and fluid retention
- Dry mouth and constipation (Correct answer)
Correct answer: Dry mouth and constipation
Tiotropium is a long-acting muscarinic antagonist (LAMA), also known as an anticholinergic. The most common side effects associated with this class of medication are anticholinergic effects, such as dry mouth and constipation.
Question 5: The use of an inhaled corticosteroid (ICS) in combination with a long-acting beta-agonist (LABA) is primarily indicated for COPD patients with which of the following characteristics?
- Mild symptoms and no history of exacerbations.
- A concomitant diagnosis of asthma. (Correct answer)
- Severe airflow limitation (GOLD 4) regardless of exacerbation history.
- A desire to avoid using two separate inhalers.
Correct answer: A concomitant diagnosis of asthma.
While dual bronchodilation (LABA/LAMA) is preferred for many COPD patients, a LABA/ICS combination is a better choice for patients who have features of asthma-COPD overlap. The GOLD guidelines also suggest considering ICS in patients with a history of exacerbations and elevated blood eosinophil counts, as eosinophils can predict a favorable response to ICS.
Question 6: A 72-year-old patient with stable but symptomatic COPD is being managed on a SABA as needed. They find they are using their rescue inhaler 4-5 times every day. What is the most appropriate recommendation a COPD educator should make?
- Continue with the SABA as it is providing relief.
- Advise the patient to have their inhaler technique checked.
- Suggest a discussion with their provider about starting a long-acting bronchodilator. (Correct answer)
- Recommend adding a daily over-the-counter mucolytic agent.
Correct answer: Suggest a discussion with their provider about starting a long-acting bronchodilator.
The frequent use of a short-acting bronchodilator (more than 2-3 times a day on a regular basis) indicates that the patient's COPD is not well-controlled. This is a clear indication for the initiation of regular maintenance therapy with a long-acting bronchodilator to provide more consistent symptom control.
COPD - CCE - Certified Chronic Obstructive Pulmonary Disease Educator Pharmacological Management Questions and Answers
A 68-year-old male with a significant smoking history is newly diagnosed with COPD.
He reports getting short of breath when walking up a single flight of stairs (mMRC Grade 2) but has had no exacerbations in the past year.
According to the 2023 GOLD guidelines, what is the most appropriate initial pharmacological treatment for this patient?